Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Human Genome

Scientists Announce Plans for Synthetic Human Genomes; Could Revolutionize Biotechnology

Genome 1Washington, DC, June 3, 2016 ― Joel Achenbach reports in The Washington Post that three weeks ago, 130 scientists, entrepreneurs and policy leaders held an invitation-only, closed-door meeting at Harvard University to discuss an ambitious plan to create synthetic human genomes.

Now, after a flurry of criticism over the secrecy of the effort, the participants have published their idea, declaring that they’re launching a project to radically reduce the cost of synthesizing genomes — a potentially revolutionary development in biotechnology that could enable technicians to grow human organs for transplantation.

The proposal, published Thursday in the journal Science, is the latest sign that biotechnology is going through a rapidly advancing but ethically fraught period. Continue reading

Rutgers Licenses Promising Mechanism for Cancer Treatment to New Company Associated with BioMotiv

Darren Carpizo, MD, PhD

Darren Carpizo, MD, PhD

New Brunswick, NJ, March 2, 2016 ― BioMotiv, a drug-development accelerator associated with The Harrington Project, has created a new biotechnology startup company, Z53 Therapeutics, to discover and develop new agents for the treatment of p53-dependent cancers using a technology from Rutgers University.

The company has licensed intellectual property that originated in the laboratory of Darren Carpizo, M.D., Ph.D., at Rutgers Cancer Institute of New Jersey with the discovery that small molecules can act as zinc metallochaperones to shuttle zinc across cell membranes and reactivate mutant p53.

As part of his drug discovery research, Carpizo established collaborations with scientists from Rutgers Translational Sciences and in the lab of Stewart Loh, Ph.D., at SUNY Upstate Medical University.

The agreement among Z53 Therapeutics, Rutgers, and SUNY Upstate provides both a license to the IP and funding to continue the research. Continue reading

NIH Researchers Identify Striking Genomic Signature Shared by Five Types of Cancer

NIH in BlueBethesda, MD, February 6, 2016 ― National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.  They also found evidence that this methylation signature may be present in many more types of cancer.

The specific signature results from a chemical modification of DNA called methylation, which can control the expression of genes like a dimmer on a light switch. Higher amounts of DNA methylation (hypermethylation), like that found by the researchers in some tumor DNA, decreases a gene’s activity.

Based on this advance, the researchers hope to spur development of a blood test that can be used to diagnose a variety of cancers at early stages, when treatments can be most effective. The study appeared Feb. 5, 2016, in The Journal of Molecular Diagnostics. Continue reading

Human Genome Project Paid Off in $966 Billion Life Sciences Boom

New York, NY, June 12, 2013 — Bloomberg reports that the $14.5 billion investment by the U.S. in the Human Genome Project, completed a decade ago, has paid off more than 60-fold in new jobs, drugs and a rapidly expanding genetics industry, an analysis has found.

The endeavor to map human DNA in its entirety created $966 billion in economic impact and $59 billion in federal tax revenue, according to the study released today by United for Medical Research and Battelle, two research advocacy groups. Continue reading